Bon Natural Life Limited cash flow statement BON
In fiscal 2025, which ended Sep 30, 2025, Bon Natural Life Limited generated $141,115 of cash from operations, up 101.8% from the year before. It spent $6,827 on capital expenditures. That left free cash flow of $134,288.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2025
Sep 30, 2025
|
FY 2024
Sep 30, 2024
|
FY 2023
Sep 30, 2023
|
FY 2022
Sep 30, 2022
|
FY 2021
Sep 30, 2021
|
|---|---|---|---|---|---|
| Operating | |||||
| Depreciation and amortization |
1
-1.8%
|
1
+16.0%
|
1
+336.8%
|
0
-4.4%
|
0
|
| Stock-based compensation |
1
+5.6%
|
1
+277.7%
|
0
-17.2%
|
—
|
0
|
| Operating cash flow |
0
+101.8%
|
-8
-1152.0%
|
-1
-229.7%
|
-0
-104.6%
|
4
|
| Investing | |||||
| Capital expenditures |
0
-3.1%
|
0
-88.6%
|
0
+123.5%
|
0
-46.6%
|
0
|
| Investing cash flow |
-10
-63459.1%
|
-0
+98.7%
|
-1
+61.2%
|
-3
+59.0%
|
-7
|
| Financing | |||||
| Debt repaid |
0
-24.6%
|
0
-78.9%
|
2
+236.4%
|
1
|
—
|
| Short-term debt issued |
12
+179.0%
|
4
+49.6%
|
3
+9.4%
|
3
+109.3%
|
1
|
| Short-term debt repaid |
7
+382.8%
|
2
-44.7%
|
3
+6591.6%
|
0
-98.4%
|
3
|
| Financing cash flow |
15
+76.5%
|
9
+657.9%
|
1
-48.9%
|
2
-57.7%
|
5
|
| Change in cash | |||||
| Net change in cash |
6
+927.3%
|
1
+175.0%
|
-1
+31.5%
|
-1
-157.4%
|
2
|
| Free cash flow |
0
+101.7%
|
-8
-1038.9%
|
-1
-216.0%
|
-0
-105.4%
|
4
|
| Per share | |||||
| Free cash flow per share |
0.05
+100.1%
|
-80.43
-336.0%
|
-18.45
-7111.1%
|
-0.26
-142.9%
|
0.60
|
| Ratios | |||||
| Free cash flow margin |
0.72%
|
-32.42%
|
-2.30%
|
-0.72%
|
15.69%
|
| Capital expenditures to revenue |
0.04%
|
0.03%
|
0.21%
|
0.09%
|
0.20%
|
| Stock-based compensation to revenue |
7.46%
|
5.54%
|
1.18%
|
—
|
1.66%
|
| Cash conversion |
—
|
-19.40x
|
-0.13x
|
-0.03x
|
0.88x
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- BON (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- Cayman Islands
- Headquarters
- Shaanxi, China
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1816815
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.